中国人口腔黏膜黑色素瘤临床诊治专家共识

doi:10.19438/j.cjoms.2021.06.001

中国口腔颌面外科杂志 ›› 2021, Vol. 19 ›› Issue (6): 481-488.doi: 10.19438/j.cjoms.2021.06.001

中国人口腔黏膜黑色素瘤临床诊治专家共识

郭伟^1,*, 任国欣¹, 孙沫逸², 孔蕴毅³, 王丽珍⁴, 步荣发⁵, 冉炜⁶, 唐瞻贵⁷, 李龙江⁸, 孟箭⁹, 孙志军¹⁰, 尚伟¹¹, 吕炯¹², 武和明¹³, 张陈平¹, 何悦¹, 马旭辉¹, 宋浩¹, 鞠侯雨¹, 郑家伟¹, 龚忠诚¹⁴, 杨凯¹⁵, 张杰¹⁶, 吴云腾^1,*

1. 上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海 200011;
2. 空军军医大学口腔医学院口腔颌面外科,陕西西安 710032;
3. 复旦大学附属肿瘤医院病理科,上海 200032;
4. 上海交通大学医学院附属第九人民医院口腔病理科,上海 200011;
5. 中国人民解放军总医院口腔科,北京 100853;
6. 中山大学附属第一医院口腔科,广东广州 510080;
7. 中南大学湘雅口腔医学院口腔颌面外科,湖南长沙 410013;
8. 四川大学华西口腔医院头颈肿瘤外科,四川成都 610000;
9. 徐州医科大学口腔医学院,徐州市中心医院口腔科,江苏徐州 221009;
10. 武汉大学口腔医学院口腔颌面-头颈肿瘤科,湖北武汉 430079;
11. 青岛大学附属医院口腔颌面外科,山东青岛 266000;
12. 浙江大学医学院附属第一医院口腔颌面外科,浙江杭州 310003;
13. 南京医科大学口腔医学院口腔颌面外科,江苏南京 210008;
14. 新疆医科大学第一附属医院口腔颌面外科,新疆乌鲁木齐 830054;
15. 重庆医科大学附属第一医院口腔颌面外科,重庆 400042;
16. 北京大学口腔医院口腔颌面外科,北京 100081

出版日期:2021-12-25 发布日期:2022-03-02
通讯作者: 吴云腾,E-mail: wuyunteng731@163.com;郭伟,E-mail:guoweicn@sjtu.edu.cn。^*共同通信作者
作者简介:郭伟（1958-），男，博士，教授、主任医师
基金资助:
上海市科学技术委员会资助项目（14DZ1941400,10410711200, 08140902100）

Expert consensus on clinical diagnosis and treatment for Chinese oral mucosal melanoma

GUO Wei¹, REN Guo-xin¹, SUN Mo-yi², KONG Yun-yi³, WANG Li-zhen⁴, BU Rong-fa⁵, RAN Wei⁶, TANG Zhan-gui⁷, LI Long-jiang⁸, MENG Jian⁹, SUN Zhi-jun¹⁰, SHANG Wei¹¹, LV Jiong¹², WU He-ming¹³, ZHANG Chen-ping¹, HE Yue¹, MA Xu-hui¹, SONG Hao¹, JU Hou-yu¹, ZHENG Jia-wei¹, GONG Zhong-cheng¹⁴, YANG Kai¹⁵, ZHANG Jie¹⁶, WU Yun-teng¹

1. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
2. Department of Oral and Maxillofacial Surgery, School of Stomatology, Air Force Medical University. Xi'an 710032, Shannxi Province;
3. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University. Shanghai 200032;
4. Department of Oral Pathology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
5. Department of Oral & Maxillofacial Surgery, People's Liberation Army Hospital. Beijing 100853;
6. Department of Stomatology, First Affiliated Hospital of Sun Yat-sen University. Guangzhou 510080, Guangdong Province;
7. Department of Oral and Maxillofacial Surgery, School of Medicine, Central South University. Changsha 410013, Hunan Province;
8. Department of Head and Neck Oncology, West China Stomatological Hospital, Sichuan University. Chengdu 610000, Sichuan Province;
9. Department of Stomatology, Xuzhou Central Hospital, School of Stomatology, Xuzhou Medical University. Xuzhou 221009, Jiangsu Province;
10. Department of Oromaxillofacial Head and Neck Oncology, Hospital of Stomatology Wuhan University. Wuhan 430079, Hubei Province;
11. Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Qingdao University. Qingdao 266000, Shandong Province;
12. Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Zhejiang University Medical College. Hangzhou 310003, Zhejiang Province;
13. Department of Oral and Maxillofacial Surgery, Nanjing Medical University Stomatology College. Nanjing 210008, Jiangsu Province;
14. Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Xinjiang Medical University. Urumqi 830054, Xinjiang Uygur Autonomous Region;
15. Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital of Chongqing Medical University. Chongqing 400042;
16. Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Peking University. Beijing 100081, China

Online:2021-12-25 Published:2022-03-02

摘要/Abstract

摘要： 头颈黏膜黑色素瘤（HNMM）是一类高度恶性的实体肿瘤,5年生存率长期徘徊在20%左右,其致病因素、驱动基因、临床表现及治疗手段等与皮肤黑色素瘤差异较大。2015年,国内首个头颈黏膜黑色素瘤诊治专家共识建立,经过6年多的推广应用, HNMM临床诊治规范性有了很大提高。随着黏膜黑色素瘤临床与基础研究的不断深入,HNMM的诊治与预后在近些年发生了较大变化,特别是头颈部各分支学科的蓬勃发展,口腔、鼻腔鼻窦、眼部等黏膜黑色素瘤各自发展出独特的诊治模式,该共识已不能满足当前临床的实际需求。对此,专家组认为头颈部黏膜包含的解剖范围较广,涉及的临床科室较多,不同学科之间黑色素瘤诊疗模式差异明显,临床亟须符合个体化治疗及精准治疗的更加专科化的诊治共识。为了进一步提高口腔黏膜黑色素瘤（OMM）的远期生存率和生存质量,让共识更好地指导临床工作,专家组聚焦 OMM,深入讨论,基于循证医学证据和经验医学,完成专家共识的制定。考虑到患者的个体化差异,本共识可作为OMM临床实践的参考。

关键词: 口腔, 黏膜黑色素瘤, 专家共识

Abstract: [Summary] Head and neck mucosal melanoma (HNMM) is a kind of highly malignant solid tumor. The 5-year survival rate of HNMM is about 20% for a long time. Its pathogenic factors, driving genes, clinical manifestations and treatment methods are quite different from skin melanoma. In 2015, the first Chinese expert consensus on the diagnosis and treatment of head and neck mucosal malignant melanoma was established. After more than six years of application, the clinical diagnosis and treatment of HNMM has been greatly improved. With the deepening of clinical and basic research on mucosal melanoma, the diagnosis, treatment and prognosis of HNMM have changed greatly in recent years, especially with the vigorous development of various branches of head and neck. Oral, nasal, sinus, eye and other mucosal melanoma have developed their own unique diagnosis and treatment model. This consensus can’t meet the actual needs of the current clinical practice. In this regard, the expert group believes that head and neck mucosa contains a wide range of anatomy, involving more clinical departments, and the diagnosis and treatment mode of melanoma varies significantly between different disciplines. It is urgent to meet the clinical consensus of more specialized diagnosis and treatment of individualized treatment and precise treatment. In order to further improve the long-term survival rate and quality of life of oral mucosal melanoma (OMM) and make the consensus to better guide clinical work, this expert group will focus on OMM and conduct in-depth discussion, and establish expert consensus based on evidence-based medicine and empirical medicine. Considering the individual differences of patients, this consensus can be used as a reference for clinical practice of OMM.

Key words: Oral cavity, Mucosal melanoma, Expert consensus

中图分类号:

R739.8

郭伟, 任国欣, 孙沫逸, 孔蕴毅, 王丽珍, 步荣发, 冉炜, 唐瞻贵, 李龙江, 孟箭, 孙志军, 尚伟, 吕炯, 武和明, 张陈平, 何悦, 马旭辉, 宋浩, 鞠侯雨, 郑家伟, 龚忠诚, 杨凯, 张杰, 吴云腾. 中国人口腔黏膜黑色素瘤临床诊治专家共识[J]. 中国口腔颌面外科杂志, 2021, 19(6): 481-488.

GUO Wei, REN Guo-xin, SUN Mo-yi, KONG Yun-yi, WANG Li-zhen, BU Rong-fa, RAN Wei, TANG Zhan-gui, LI Long-jiang, MENG Jian, SUN Zhi-jun, SHANG Wei, LV Jiong, WU He-ming, ZHANG Chen-ping, HE Yue, MA Xu-hui, SONG Hao, JU Hou-yu, ZHENG Jia-wei, GONG Zhong-cheng, YANG Kai, ZHANG Jie, WU Yun-teng. Expert consensus on clinical diagnosis and treatment for Chinese oral mucosal melanoma[J]. China J Oral Maxillofac Surg, 2021, 19(6): 481-488.

参考文献

[1] 吴云腾, 任国欣, 孙沫逸, 等. 中国头颈黏膜黑色素瘤临床诊治专家共识[J]. 中国口腔颌面外科杂志, 2015, 13(3): 262-269.
[2] Zito PM, Mazzoni T.Oral melanoma[M]. Treasure Island: StatPearls Publishing, 2021.
[3] Schmidt MQ, David J, Yoshida EJ, et al.Predictors of survival in head and neck mucosal melanoma[J]. Oral Oncol, 2017, 73: 36-42.
[4] Lee RJ, Lee SA, Lin T, et al.Determining the epidemiologic, outcome, and prognostic factors of oral malignant melanoma by using the Surveillance, Epidemiology, and End Results database[J]. J Am Dent Assoc, 2017, 148(5): 288-297.
[5] Hicks MJ, Flaitz CM.Oral mucosal melanoma: epidemiology and pathobiology[J]. Oral Oncol, 2000, 36(2):152-169.
[6] Cui C, Lian B, Zhou L, et al.Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients[J]. Ann Surg Oncol, 2018, 25(8):2184-2192.
[7] Sun S, Huang X, Gao L, et al.Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution[J]. Oral Oncol, 2017, 74: 115-122.
[8] Albuquerque DM, Cunha JL, Roza AL, et al.Oral pigmented lesions: a retrospective analysis from Brazil[J]. Med Oral Patol Oral Cir Bucal, 2021, 26(3): e284-e291.
[9] Yamada SI, Kurita H, Kamata T, et al: Clinical investigation of 38 cases of oral mucosal melanoma: a multicentre retrospective analysis in Japan[J]. Australas J Dermatol, 2017, 58(4): e223-e227.
[10] Moya-Plana A, Mangin D, Blanchard P, et al.Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma[J]. Head Neck, 2021, 43(8): 2325-2331.
[11] Wu Y, Zhong Y, Li C, et al.Neck dissection for oral mucosal melanoma: caution of nodular lesion[J]. Oral Oncol, 2014, 50(4): 319-324.
[12] Oranges CM, Sisti G, Nasioudis D, et al.Hard palate melanoma: a population-based analysis of epidemiology and survival outcomes[J]. Anticancer Res, 2018, 38(10): 5811-5817.
[13] Wu Y, Wang L, Ma X, et al.The existence of early stage oral mucosal melanoma: a 10-year retrospective analysis of 170 patients in a single institute[J]. Oral Oncol, 2018, 87: 70-76.
[14] Young A, Okuyemi OT.Malignant tumors of the palate[M]. Treasure Island: StatPearls Publishing, 2021.
[15] Kumar V, Vishnoi JR, Kori CG, et al.Primary malignant melanoma of oral cavity: a tertiary care center experience[J]. Natl J Maxillofac Surg, 2015, 6(2): 167-171.
[16] Femiano F, Lanza A, Buonaiuto C, et al.Oral malignant melanoma: a review of the literature[J]. J Oral Pathol Med, 2008, 37(7): 383-388.
[17] Eisen D, Voorhees JJ.Oral melanoma and other pigmented lesions of the oral cavity[J]. J Am Acad Dermatol, 1991, 24(4): 527-537.
[18] Lian B, Cui CL, Zhou L, et al.The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients[J]. Ann Oncol, 2017, 28(4): 868-873.
[19] Flukes S, Lohia S, Barker CA, et al.Are our patients doing better? a single institution experience of an evolving management paradigm for sinonasal mucosal melanoma[J]. Oral Oncol, 2021, 112:105006.
[20] Soares CD, Carlos R, Andrade BAB, et al.Oral amelanotic melanomas: clinicopathologic features of 8 cases and review of the literature[J]. Int J Surg Pathol, 2021, 29(3): 263-272.
[21] Igarashi H, Fukuda M, Konno Y, et al.Abscopal effect of radiation therapy after nivolumab monotherapy in a patient with oral mucosal melanoma: a case report[J]. Oral Oncol, 2020, 108: 104919.
[22] Zhang J, Yu M, Li X, et al.Combination therapy improves immune response and prognosis in patients with advanced oral mucosal melanoma: a clinical treatment success[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(4): 307-316.
[23] Mehnert JH, Heard JL.Staging of malignant melanomas by depth of invasion; a proposed index to prognosis[J]. Am J Surg, 1965, 110: 168-176.
[24] Clark WH Jr, Ainsworth AM, Bernardino EA, et al.The developmental biology of primary human malignant melanomas[J]. Semin Oncol, 1975, 2(2): 83-103.
[25] Zhou S, Sikorski D, Xu H, et al.Defining the criteria for reflex testing for BRAF mutations in cutaneous melanoma patients[J]. Cancers (Basel), 2021, 13(9): 2282-2300.
[26] Bastian BC.The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia[J]. Annu Rev Pathol, 2014, 9:239-271.
[27] van Breeschoten J, Wouters M, Hilarius DL, et al. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis[J]. Br J Cancer, 2021, 124(7):1222-1230.
[28] Ishizaki T, Yamazaki J, Jelinek J, et al.Genome-wide DNA methylation analysis identifies promoter hypermethylation in canine malignant melanoma[J]. Res Vet Sci, 2020, 132: 521-526.
[29] Chen F, Zhang Q, Wang Y, et al.KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature[J]. Oncol Lett, 2018, 15(6):9786-9792.
[30] Millán-Esteban D, García-Casado Z, Manrique-Silva E, et al. Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients[J]. Eur J Dermatol, 2021 Mar 1.
[Online ahead of print]
[31] Cai YJ, Ke LF, Zhang WW, et al.Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract[J]. BMC Cancer, 2021, 21(1): 677-686.
[32] Rawson RV, Wilmott JS, Scolyer RA.Mucosal melanoma: a review emphasizing the molecular landscape and implications for diagnosis and management[J]. Surg Pathol Clin, 2021, 14(2): 293-307.
[33] Lyu J, Miao Y, Yu F, et al. CDK4 and TERT amplification in head and neck mucosal melanoma[J]. J Oral Pathol Med, 2021 Apr 2.
[Online ahead of print]
[34] Zhou R, Shi C, Tao W, et al.Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations[J]. Clin Cancer Res, 2019, 25(12): 3548-3560.
[35] Lyu J, Song Z, Chen J, et al.Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets[J]. J Pathol, 2018, 244(3): 358-366.
[36] Kim HS, Jung M, Kang HN, et al.Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition[J]. Oncogene, 2017, 36(23): 3334-3345.
[37] Mizrahi JD, Surana R, Valle JW, et al.Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020.
[38] Vora GK, Demirci H, Marr B, et al.Advances in the management of conjunctival melanoma[J]. Surv Ophthalmol, 2017, 62(1):26-42.
[39] Rigel DS, Friedman RJ, Kopf AW, et al.ABCDE--an evolving concept in the early detection of melanoma[J]. Arch Dermatol, 2005, 141(8): 1032-1034.
[40] Ma X, Wu Y, Zhang T, et al.The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China[J]. Oncotarget, 2017, 8(47): 82661-82673.
[41] Ma X, Wu Y, Zhang T, et al.Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases[J]. J Cancer, 2017, 8(18): 3828-3837.
[42] Agarwala SS, Keilholz U, Gilles E, et al.LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)[J]. Eur J Cancer, 2009,45(10): 1807-1814.
[43] Wang X, Wu HM, Ren GX, et al.Primary oral mucosal melanoma: advocate a wait-and-see policy in the clinically N0 patient[J]. J Oral Maxillofac Surg, 2012, 70(5):1192-1198.
[44] Nenclares P, Ap Dafydd D, Bagwan I, et al.Head and neck mucosal melanoma: the United Kingdom national guidelines[J]. Eur J Cancer, 2020, 138: 11-18.
[45] Cui C, Mao L, Chi Z, et al.A phase Ⅱ, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J]. Mol Ther, 2013, 21(7):1456-1463.
[46] Ascierto PA, Del Vecchio M, Mandalá M, et al.Adjuvant nivolumab versus ipilimumab in resected stage ⅢB-C and stage Ⅳ melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(11): 1465-1477.
[47] Sheng X, Yan X, Chi Z, et al.Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell Death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial[J]. J Clin Oncol, 2019, 37(32): 2987-2999.

中国人口腔黏膜黑色素瘤临床诊治专家共识

Expert consensus on clinical diagnosis and treatment for Chinese oral mucosal melanoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	何冉, 侯德强. 口腔颌面部肿瘤患者围术期症状群与生活质量相关性研究[J]. 中国口腔颌面外科杂志, 2024, 22(5): 446-454.
[3]	赵安玉琢, 石兴莲, 刘欢, 姜健红, 李哲臻, 刘梅. 人工智能在口腔癌早期诊断中的应用研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(5): 493-498.
[4]	邰茂众, 秦中平, 郑家伟, 李克雷, 刘学键, 李凯, 袁斯明, 范新东, 周德凯, 董长宪, 吉毅, 顾松, 霍然, 杨耀武, 王绪凯. 局限性血管内凝血诊断与治疗中国专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(4): 313-321.
[5]	何禹龙, 包崇云. 基于CBCT图像分析下颌第三磨牙阻力来源的人工智能口腔外科医师[J]. 中国口腔颌面外科杂志, 2024, 22(4): 339-345.
[6]	刘敏, 张咏梅, 袁卫军, 侯黎莉. 护士口腔颌面创伤应急处置能力评估问卷的构建及初步应用[J]. 中国口腔颌面外科杂志, 2024, 22(4): 346-352.
[7]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[8]	高鹏飞, 林洁. 区域神经阻滞技术用于口腔癌缺损皮瓣修复手术的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(4): 400-403.
[9]	王婷, 罗涛, 支延康, 孙宇. 负载利多卡因的透皮给药系统在口腔颌面部疼痛中的应用效果评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 222-227.
[10]	洪磊, 陈伟良. 口腔癌老年患者术后静脉血栓栓塞症的危险因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(3): 233-238.
[11]	王帅, 何杏芳, 王蕴洁, 吴伟勤, 黄秋雨. 非药物干预对口腔癌患者术后谵妄预防效果的系统评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 279-286.
[12]	孙晓梅, 段晓峰. 去泛素化酶在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(3): 294-299.
[13]	王延安, 秦中平, 郑家伟, 李春洁, 刘少华, 杨耀武, 陈刚, 陈伟良, 刘学键, 杜仲, 张雷, 王业飞, 王德明, 苏立新, 谢峰, 董长宪, 郭磊, 李凯, 顾松, 何悦, 张志愿. 头颈部血管瘤及脉管畸形手术治疗专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(2): 105-117.
[14]	李锦存, 翟堃, 胡晨, 刘絮影, 马兴平, 马坚. 整合WGNCA和PPI网络鉴定口腔鳞状细胞癌的关键基因[J]. 中国口腔颌面外科杂志, 2024, 22(2): 128-136.
[15]	张银银, 朱岩岩, 丁嘉慧, 孙玉华. 144例口腔颌面部间隙感染并发症及入ICU监护的危险因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(2): 148-152.